

# Cigna National Preferred Formulary Coverage Policy



Effective Date ..... 1/1/2021  
Next Review Date... 1/1/2022  
Coverage Policy Number ..... NPF334

## Prior Authorization

### Contraceptives – Phexxi™ (lactic acid, citric acid, and potassium bitartrate vaginal gel)

#### Table of Contents

NPF Coverage Policy .....	1
Background.....	2
References .....	2
Last Revision Details .....	2

#### Related Coverage Resources

#### INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

## NPF Coverage Policy

**Cigna covers lactic acid, citric acid, and potassium bitartrate (Phexxi™) as medically necessary when the following criteria are met for FDA Indication(s) or Other Uses with Supportive Evidence:**

Prior Authorization is recommended for prescription benefit coverage of Phexxi. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days.

#### FDA Indication(s)

- 1. Prevention of Pregnancy.** Approve for 6 months. Approve if according to the prescribing physician, other formulary contraceptives would not be as medically appropriate for the patient as the requested non-formulary drug.

\*\*Criterion developed in accordance with the Affordable Care Act, HRSA Guidelines, and PHS Act section 2713.

## Background

### Overview

Phexxi is indicated for the **prevention of pregnancy** in females of reproductive potential for use as an on-demand method of contraception.<sup>1</sup> Limitation of Use: Phexxi is not effective for the prevention of pregnancy when administered after intercourse.

Phexxi contains lactic acid, citric acid, and potassium bitartrate; *in vitro* studies show that a pH lowering effect and sperm motility reduction contribute to the activity of the product in the vagina.<sup>1</sup> Phexxi has been previously known under multiple names, such as Amphora, Acidform, and was historically available as an over-the-counter (OTC) personal lubricant.<sup>2</sup> The recommended dose of Phexxi is one pre-filled applicator (5 grams) vaginally administered immediately before or up to one hour before each act of vaginal intercourse.<sup>1</sup> If more than one act of vaginal intercourse occurs within one hour, an additional dose must be used.

## References

1. Phexxi™ vaginal gel [prescribing information]. San Diego, CA: Evofem Biosciences, Inc.; July 2020.
2. Nelson AL. An overview of properties of Amphora (Acidform) contraceptive vaginal gel. *Expert Opin Drug Saf.* 2018;17(9):935-943.
3. Simoes JA, Bahamondes LG, Camargo R, et al. A pilot clinical trial comparing an acid-buffering formulation (Acidform gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis. *Br J Clin Pharmacol.* 2006;61(2):211-17.

## Last Revision Details

New Policy	--	11/04/2020
------------	----	------------

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2021 Cigna.